Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.93 +2.1%	$4.37	$3.21 ▼ $8.06	$940.27M	0.76	4.46 million shs	3.92 million shs
COLL Collegium Pharmaceutical	$29.23 -0.3%	$28.00	$23.23 ▼ $42.29	$939.22M	0.63	421,106 shs	323,265 shs
EPZM Epizyme	$1.47	$1.47	$0.41 ▼ $5.80	$247.44M	-0.41	3.23 million shs	7,960 shs
PAHC Phibro Animal Health	$24.32 -1.1%	$20.58	$16.16 ▼ $26.55	$985.79M	0.62	202,765 shs	245,008 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+3.49%	-3.02%	-6.78%	-28.84%	-43.88%
COLL Collegium Pharmaceutical	-0.27%	+1.56%	+6.00%	+4.53%	-11.56%
EPZM Epizyme	0.00%	0.00%	0.00%	0.00%	0.00%
PAHC Phibro Animal Health	0.00%	+5.77%	+26.18%	+2.12%	+39.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.6206 of 5 stars	4.5	3.0	0.0	4.4	2.2	2.5	0.6
COLL Collegium Pharmaceutical	4.1614 of 5 stars	3.4	0.0	0.0	3.0	4.2	0.8	2.5
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	3.7495 of 5 stars	0.8	3.0	2.5	1.1	3.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.90	Moderate Buy	$10.39	164.35% Upside
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.80	49.85% Upside
EPZM Epizyme	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-17.76% Downside

Current Analyst Ratings Breakdown

Latest EPZM, PAHC, ARDX, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/7/2025	ARDX Ardelyx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/7/2025	ARDX Ardelyx	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$11.00
3/4/2025	ARDX Ardelyx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$361.71M	2.60	N/A	N/A	$0.73 per share	5.38
COLL Collegium Pharmaceutical	$664.28M	1.41	$10.59 per share	2.76	$5.99 per share	4.88
EPZM Epizyme	$37.43M	6.61	N/A	N/A	($0.54) per share	-2.72
PAHC Phibro Animal Health	$1.19B	0.83	$2.24 per share	10.87	$6.09 per share	3.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	12.68	N/A	-11.73%	-24.87%	-10.51%	7/30/2025 (Estimated)
COLL Collegium Pharmaceutical	$48.15M	$1.22	12.60	4.86	N/A	14.78%	104.67%	18.38%	8/14/2025 (Estimated)
EPZM Epizyme	-$251.12M	-$1.72	N/A	N/A	N/A	-391.90%	-2,459.33%	-69.74%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	50.67	11.58	0.45	1.75%	25.35%	6.21%	N/A

Latest EPZM, PAHC, ARDX, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.97%	N/A	61.54%	N/A

Latest EPZM, PAHC, ARDX, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.87	4.58	4.31
COLL Collegium Pharmaceutical	3.43	0.97	0.88
EPZM Epizyme	N/A	5.35	5.19
PAHC Phibro Animal Health	2.99	3.20	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
COLL Collegium Pharmaceutical	N/A
EPZM Epizyme	76.45%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
COLL Collegium Pharmaceutical	2.51%
EPZM Epizyme	23.40%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	222.88 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
EPZM Epizyme	250	168.33 million	128.97 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable

EPZM, PAHC, ARDX, and COLL Headlines

Recent News About These Companies

3 Stocks Showing Positive Momentum Despite Trade Tensions

June 3 at 4:00 PM | zacks.com

Summit Global Investments Has $811,000 Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 6:08 AM | marketbeat.com

Ameriprise Financial Inc. Purchases 21,576 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 3:19 AM | marketbeat.com

Jane Street Group LLC Trims Stock Position in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 3:19 AM | marketbeat.com

Kings Path Partners LLC Buys New Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31 at 6:11 AM | marketbeat.com

Millennium Management LLC Has $4.36 Million Position in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31 at 3:28 AM | marketbeat.com

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

May 29, 2025 | zacks.com

Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why

May 28, 2025 | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

May 28, 2025 | zacks.com

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

May 28, 2025 | zacks.com

Man Group plc Purchases Shares of 23,836 Phibro Animal Health Co. (NASDAQ:PAHC)

May 28, 2025 | marketbeat.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Purchased by Nuveen Asset Management LLC

May 28, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Trims Stock Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

May 28, 2025 | marketbeat.com

Research Analysts Issue Forecasts for PAHC FY2025 Earnings

May 27, 2025 | marketbeat.com

Research Analysts Set Expectations for PAHC FY2025 Earnings

May 25, 2025 | marketbeat.com

Zacks Research Has Bullish Outlook for PAHC FY2025 Earnings

May 25, 2025 | americanbankingnews.com

4 Stocks Trading Near 52-Week High With Room to Rise Further

May 23, 2025 | zacks.com

Best Growth Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

Best Value Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

Best Income Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Bought by Northern Trust Corp

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPZM, PAHC, ARDX, and COLL Company Descriptions

Ardelyx NASDAQ:ARDX

$3.93 +0.08 (+2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.93 0.00 (-0.03%)

As of 07:40 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$29.23 -0.08 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$29.24 +0.02 (+0.05%)

As of 04:40 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$24.32 -0.26 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$24.32 0.00 (-0.02%)

As of 04:20 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time